ReviewInternational journal of clinical oncology2025
Onco-nephrology in clinical practice: pharmacokinetics, monitoring, and treatment strategies for patients with cancer and impaired renal function.
Review in International journal of clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacokinetic and pharmacogenomic profile of capecitabine and oxaliplatin in a patient with gastric cancer undergoing hemodialysis: a case report.Cancer chemotherapy and pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal dysfunction is common in patients with cancer and affects their pharmacokinetics, thereby altering treatment efficacy and safety. This review outlines the principles of dose adjustment based on renal function and highlights specific issues in patients undergoing dialysis or with proteinuria. In patients undergoing dialysis, dose adjustment can be rational if drug properties such as molecular weight and protein binding are considered. Metabolites of some drugs, such as fluorouracil (5-FU), may accumulate in patients with impaired renal function, thereby increasing the risk of toxicity. For oxaliplatin, increased platinum exposure in patients undergoing dialysis does not necessarily increase toxicity, possibly because reactive platinum species are eliminated independent of renal function. Proteinuria can lead to reduced drug exposure to monoclonal antibodies owing to abnormal urinary excretion. The early detection and management of drug-induced kidney injuries are essential. These strategies include identifying risk factors, adjusting doses, and implementing monitoring systems. Protocol-based approaches, such as pharmacist-led monitoring, can improve cancer pharmacotherapy. Automated systems and AI-based models have also been explored for risk prediction. Future studies should focus on deepening our understanding of pharmacokinetics in patients with advanced chronic kidney disease (CKD) or those on dialysis. Multidisciplinary collaboration in onco-nephrology is important to improve cancer care in this growing population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.